Having a vaccine is wonderful...However, it does not eradicate COVID-19.
The last several months have clearly shown the uncertainty surrounding COVID-19. What percentage of the population will be willing to get the vaccine? Will the vaccinated require re-vaccination or “booster shots?” How will the new Delta variant affect us? What other variants of COVID are still to come?
How does COVID affect the world beyond the US borders? The rest of the world does not have access to the vaccine like we do in the U.S. For example, as of June 2021, Ecuador has less than 5% of their population vaccinated.
According to a research study completed in September 2020, 49% of Americans said they would definitely NOT, or probably NOT take a COVID-19 vaccine. In November 2020, our team estimated what the mid-2021 vaccination rates would be. As of June 1, 2021, our data is near accurate, validating our projections and expectations. More than 162 million Americans are still susceptible to COVID-19. It is not over.
We know now that the vaccine does not guarantee lifetime immunity, and people can catch COVID-19 multiple times. We also know that people will have to get re-vaccinated.
Millions of Americans, and billions worldwide will still need to protect themselves from the serious effects of COVID.
Consider that even people who are vaccinated will still need to be tested because vaccinated people are still getting sick and developing long-term conditions from the virus. In addition, previously infected individuals can catch the disease again. Humanity has never had to eradicate a SARS virus before; therefore, we do not actually know how long immunity will last. The world still needs testing so that people with the virus can be identified and helped.
All of these factors demonstrate the need for a highly effective therapy
to treat those facing life-threatening symptoms of COVID.
Dr. Aury Nagy, M.D. FAANS
FOUNDER & EXECUTIVE CHAIRMAN
Las Vegas native Aury Nagy, M.D. FAANS is a neurosurgeon practicing in Las Vegas. He serves on the Nevada State Board of Medical Examiners, is the past chairman of the Department of Neurosurgery at the University Medical Center of Southern Nevada.
Additionally, Dr. Nagy served on the Federal Advisory Committee to Congress on Health Information Technology, was chairman of the board of the FQHC Searchlight Healthcare Charities, was a founding board member of First Security Bank of Nevada and served on the Nevada Governor’s Workforce Board for Nevada. Dr. Nagy is a graduate of Yale University, Baylor College of Medicine and George Washington School of Medicine Department of Neurological Surgery. He has studied at Stanford, Harvard, Duke, Cal Western, LSU, University of Arizona and the University of Pennsylvania. Dr. Nagy was awarded the Harvey Cushing Clinical Fellowship by the Congress of Neurological Surgeons and used the funds at the direction of the chairman of the grants awards committee for the neurosciences at the National Institute of Health to study the brain machine interface and functional electrical stimulation to investigate possibilities for spinal cord injury bypass. Prior to that, he collaborated with Los Alamos National Laboratories on a project utilizing swept frequency acoustic interferometry to determine intracranial pressure in victims of traumatic brain injury.
Board & Leadership
Aury Nagy, MD. FAANS
Executive Chairman of the Board and Chief Science Officer
Dr. Nagy is a Neurosurgeon based in Las Vegas and is a board member of the Nevada State Medical Board and former Chief of Neurosurgery at University Medical Center. Additionally, Dr. Nagy served on the Federal Advisory Committee to Congress on Health Information Technology, was chairman of the board of the Federally Qualified Health Center (FQHC) Searchlight Healthcare Charities, was a founding board member of First Security Bank of Nevada and served on the Nevada Governor's Workforce Board for Nevada.
Dr. Nagy is a graduate of Yale University, Baylor College of Medicine, and George Washington School of Medicine Department of Neurological Surgery. He has studied at Stanford, Harvard, Duke, Cal Western, LSU, University of Arizona, and the University of Pennsylvania. Dr. Nagy was awarded the Harvey Cushing Clinical Fellowship by the Congress of Neurological Surgeons and used the funds at the direction of the chairman of the grants awards committee for the neurosciences at the National Institute of Health to study the brain-machine interface and functional electrical stimulation to investigate possibilities for spinal cord injury bypass. Before that, he collaborated with Los Alamos National Laboratories on a project utilizing swept frequency acoustic interferometry to determine intracranial pressure in traumatic brain injury victims.
Jamie Jones
CEO
Jamie Jones has 30 years of expertise in the life sciences industry as a senior leader in Marketing, Sales, Commercialization, Business Development, and Corporate Strategy. Jamie held C-suite positions at Kalos Therapeutics and DoubleRainbow Biosciences before joining CovInnovations. His track record of success includes global and regional operations, over ten drug launches, engineered commercial startups on three continents, and an award-winning industry executive for innovation, groundbreaking marketing, and sales strategies. Jamie graduated with an MBA in Marketing and a BS in Finance from the University of Central Florida.
Kristine Leavitt, MSN
Board Member
Kristine Leavitt is a board-certified nurse practitioner in family medicine, hospice, and palliative care. Ms. Leavitt was the former program coordinator for the University Medical Center of Southern Nevada's transplant program. She received her Master of Science in Nursing (MSN) from the University of Nevada – Las Vegas.
Elliot Goldstein, MD
Board Member
Elliot Goldstein is the founder and former CEO of ProMIS Neurosciences, Inc. (Toronto: PMN.TO, CAD 56 million market cap). ProMIS is a development-stage biotech company that discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). He has 30 years of experience bringing products through the FDA to market, including cyclosporine (an anti-inflammatory small molecule drug product).
Eric Henderson
Board Member
Eric Henderson is the founder and CEO of XCBG consulting. He has contributed to US companies securing approximately $25 billion in projects financed annually by the World Bank and assisting the US and global companies and NGOs with participating in World Bank-financed procurement opportunities in more than 150 countries. Mr. Henderson earned an MA in international relations and affairs from American University.
Maggie Arias-Petrel
Board Member
Maggie Arias-Petrel is the Vice President of Operations for Cano Health (NYSE: CANO, $1.1 billion market cap) and is Chairwoman of the Board for Dignity Health and Commissioner of the Nevada State Board of Medical Examiners. She is active in both local and foreign governments to advance health care.
Ibrahim Pataudi
Board Member
Ibrahim Pataudi is a Vice President of Business Development for NuID, a blockchain company with National Security Agency (NSA) contracts. Mr. Pataudi earned a bachelor's degree in International Relations and Affairs from Claremont McKenna College.
Wayne Jefferies
Board Member
Wayne Jefferies is a member of the Board of Directors for Medivolve and has secured large deals for COVID-related clinics across the US. Medivolve is a healthcare technology and services company that seeks to reinvent the US healthcare system by leveraging a bespoke telehealth platform, a clinical diagnostic network, and a data-driven AI framework to improve patient care.
Dr. Manuel Baldeon
Board Member
Dr. Manuel Baldeon is a Harvard-trained professor of immunology and former secretary of science and technology for Ecuador who helped the company compile the clinical trial protocol submitted to the FDA. Dr. Baldeon earned a Ph.D. in Nutritional Immunology from the University of Illinois Urbana-Champaign.
Mansoor Ijaz
Board Member
Mansoor Ijaz is the founder and CEO of Crescent Global Partners. Mr. Ijaz is a proprietary trader and hedge-fund manager who founded Crescent Investment Management in New York in 1990. Crescent, and its successor companies, operate CARAT, a proprietary trading system developed by Ijaz in the late 1980s during his graduate research studies at MIT.
PLEASE FILL THE FORM BELOW OR CALL US AT (833) 702-1888
